The World Health Organization (WHO) developed a structured approach to pain management in 1986, originally designed for cancer pain but now widely used as a framework for treating pain of all kinds. At its core is the WHO analgesic ladder, a three-step system that matches the strength of pain medication to the severity of pain. The approach remains one of the most recognized pain treatment frameworks in global medicine.
The Three-Step Analgesic Ladder
The WHO ladder works on a simple principle: start with the mildest effective treatment and move up only when pain isn’t adequately controlled. Each step corresponds to a level of pain intensity, assessed using a standard pain scale.
- Step 1 (mild pain): Non-opioid pain relievers like acetaminophen or anti-inflammatory drugs such as ibuprofen, with or without adjuvant medications.
- Step 2 (moderate pain): Weak opioids, often combined with non-opioid medications from Step 1. Adjuvant drugs can be added as needed.
- Step 3 (severe pain): Strong opioids, again potentially combined with non-opioid and adjuvant medications.
Adjuvant medications are drugs that aren’t primarily painkillers but help with specific types of pain. For nerve-related pain, for example, commonly used adjuvants include antidepressants and anticonvulsants. Steroids are sometimes added for inflammation or swelling that contributes to pain. In one study of patients with nerve-related cancer pain, the most frequently used adjuvants were an antidepressant (about 30% of patients), an anticonvulsant (30%), and a steroid (20%), often in combination with opioids.
Five Guiding Principles
The WHO framework isn’t just about which drugs to use. It spells out how pain medication should be given, organized around a set of guiding principles sometimes summarized as “by the mouth, by the clock, by the ladder, for the individual, and with attention to detail.”
By the mouth means oral medication is preferred over injections or IVs whenever possible. This keeps treatment simple and accessible, especially in settings with limited medical infrastructure. By the clock means medications are taken on a regular schedule, not just when pain flares up. Staying ahead of pain is far more effective than chasing it after it returns. By the ladder is the stepwise approach described above.
For the individual reflects the WHO’s position that there is no standardized dose in pain treatment. What works for one person may be completely inadequate for another, so dosing should be tailored to each patient’s response. Attention to detail emphasizes that skipping doses or changing a regimen without careful monitoring can cause pain to break through again. Consistent adherence matters.
How It Applies to Cancer Pain
Cancer pain remains the primary context for the WHO ladder, and current oncology guidelines build directly on its framework. For moderate to severe cancer pain, opioids are the standard recommendation unless a specific reason prevents their use. Treatment typically starts with immediate-release, as-needed dosing so clinicians can find the right amount before switching to a regular schedule.
Dose adjustments are made as a percentage of the total daily dose, usually in increases of 25% to 50%, depending on the person’s overall health, organ function, and frailty. For patients already on a regular opioid schedule, a separate “breakthrough” dose of a fast-acting opioid is kept available, generally calculated at 5% to 20% of their total daily dose.
Not all opioids are considered equally suitable. Some require specific liver enzymes to become active in the body, meaning they simply don’t work well for a significant percentage of people who lack those enzymes. This genetic variability makes certain medications less reliable choices, and clinicians are advised to consider each drug’s properties carefully rather than defaulting to one option.
Pain Management in Children
The WHO issued updated guidance recognizing that children require a fundamentally different approach to pain care than adults. Between one-quarter and one-third of children experience chronic pain, defined as pain lasting more than three months. That kind of persistent pain can interfere with emotional, psychological, physical, and social development.
The pediatric guideline places significant emphasis on biopsychosocial factors: the child’s age, social environment, and cultural background all shape how pain should be managed. Children are physically and developmentally different from adults, so simply scaling down adult protocols isn’t adequate. The WHO recommends that treatment plans account for the whole context of a child’s life, not just the physical sensation of pain.
The Proposed Fourth Step
The original ladder has three steps, but pain specialists have increasingly advocated for a fourth step for patients whose pain doesn’t respond to even strong opioids. This step involves interventional procedures: nerve blocks, epidural injections, spinal drug delivery systems, and other techniques that target pain signals more directly. While the WHO has not formally added this step to the ladder, it’s widely referenced in pain medicine as a natural extension of the framework for the most difficult-to-treat cases.
Global Access Barriers
One of the WHO’s central concerns is that effective pain treatment remains unavailable to millions of people worldwide. The organization maintains a Model List of Essential Medicines that includes both non-opioid and opioid pain relievers, and it recommends that these medicines be available to all patients at all times at an affordable price.
In practice, that goal is far from reality. Many countries have restrictive regulations around controlled substances that make it difficult for patients to access even basic opioid medications for severe pain. Fear of addiction, limited prescriber training, supply chain problems, and regulatory complexity all contribute to what the WHO recognizes as a global treatment gap. The organization provides technical support to member states working to develop national pain management policies and encourages governments to balance the need for drug regulation with the ethical obligation to treat suffering.
The WHO is currently in the process of revising its pain management guidelines and has published interim resources for countries that need guidance while the update is underway. The revision aims to reflect newer evidence on both the benefits and risks of pain medications, particularly the complex role of opioids in chronic pain outside of cancer treatment.